Drug Profile
DAC:MMPI
Latest Information Update: 19 Nov 2003
Price :
$50
*
At a glance
- Originator ConjuChem Biotechnologies; Servier
- Class
- Mechanism of Action Angiogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 08 Oct 2001 Discontinued - Preclinical for Cancer in Canada (unspecified route)
- 08 Oct 2001 Servier is no longer involved in the development of DAC: MMPI
- 08 Nov 2000 Preclinical development for Cancer in Canada (Unknown route)